XOMA Royalty Completes Acquisition of LAVA Therapeutics N.V.

Acquisition Announcement: XOMA Royalty Corporation has completed its acquisition of LAVA Therapeutics N.V., with LAVA shareholders receiving $1.04 in cash per share and a contingent value right (CVR) for potential future payments.

Strategic Benefits: The acquisition is expected to enhance XOMA's portfolio by adding two early-stage bispecific antibodies developed in collaboration with major oncology partners, potentially driving significant value for both XOMA and LAVA shareholders.

Tender Offer Details: The tender offer for LAVA shares concluded with approximately 91.1% of outstanding shares validly tendered, leading to a corporate reorganization that resulted in XOMA acquiring 100% of LAVA.

Future Outlook: XOMA Royalty emphasizes the potential for future economic benefits from LAVA's partnered and unpartnered programs, while also cautioning that forward-looking statements regarding these benefits are subject to various risks and uncertainties.